Victor Peperzak

Utrecht, UT, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

3D bioluminescence imaging assays for measuring in vitro CAR T cell cytotoxicity.

3D bioluminescence imaging assays for measuring in vitro CAR T cell cytotoxicity.

Journal: Methods in cell biology

Published: July 13, 2026

Author Correction: Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation.

Author Correction: Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation.

Journal: Nature communications

Published: April 13, 2026

Impact of 3D cell culture hydrogels derived from basement membrane extracts or nanofibrillar cellulose on CAR-T cell activation.

Impact of 3D cell culture hydrogels derived from basement membrane extracts or nanofibrillar cellulose on CAR-T cell activation.

Journal: iScience

Published: February 04, 2025

Bridging the gap between scientific discoveries and clinical application at the Utrecht Science Park.

Bridging the gap between scientific discoveries and clinical application at the Utrecht Science Park.

Journal: Immunology and cell biology

Published: December 07, 2023

Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation.

Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation.

Journal: Nature communications

Published: November 21, 2023

Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation.

Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation.

Journal: Nature communications

Published: November 21, 2023

Identifying clinical response to daratumumab therapy in relapsed/refractory multiple myeloma using a patient-derived in vitro model.

Identifying clinical response to daratumumab therapy in relapsed/refractory multiple myeloma using a patient-derived in vitro model.

Journal: EJHaem

Published: August 07, 2023

Nivolumab plus Brentuximab vedotin +/- bendamustine combination therapy: a safe and effective treatment in pediatric recurrent and refractory classical Hodgkin lymphoma.

Nivolumab plus Brentuximab vedotin +/- bendamustine combination therapy: a safe and effective treatment in pediatric recurrent and refractory classical Hodgkin lymphoma.

Journal: Frontiers in immunology

Published: May 26, 2023

Dinaciclib synergizes with BH3 mimetics targeting BCL-2 and BCL-XL in multiple myeloma cell lines partially dependent on MCL-1 and in plasma cells from patients.

Dinaciclib synergizes with BH3 mimetics targeting BCL-2 and BCL-XL in multiple myeloma cell lines partially dependent on MCL-1 and in plasma cells from patients.

Journal: Molecular oncology

Published: May 08, 2023

Serpin B9 controls tumor cell killing by CAR T cells.

Serpin B9 controls tumor cell killing by CAR T cells.

Journal: Journal for immunotherapy of cancer

Published: March 03, 2023

Wnt inhibitors reduce the unfolded protein response and enhance bortezomib-induced cell death in multiple myeloma.

Wnt inhibitors reduce the unfolded protein response and enhance bortezomib-induced cell death in multiple myeloma.

Journal: Blood advances

Published: June 27, 2022

Multiple Myeloma Relapse Is Associated with Increased NFκB Pathway Activity and Upregulation of the Pro-Survival BCL-2 Protein BFL-1.

Multiple Myeloma Relapse Is Associated with Increased NFκB Pathway Activity and Upregulation of the Pro-Survival BCL-2 Protein BFL-1.

Journal: Cancers

Published: July 23, 2021

Showing 1-12 of 31

Last Updated: 09/26/2026